- Recommendation ID
- NG191/9
- Question
What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people and children?
- Any explanatory notes
(if applicable) Suggested PICO (Population, Intervention, Comparator, Outcome)
P: Adults, young people and children who have COVID-19 and are not in hospital
Subgroups of particular interest:
• People 18 to 49 years
• Children and young people
I: Inhaled budesonide
C: Inhaled placebo (to accommodate blinding)
O:
• All-cause mortality
• Hospitalisation
• Need for oxygen therapy (including thresholds for this decision)
• Costs of treatment
• Time to recovery
• Health-related quality of life
• Adverse events
Source guidance details
- Comes from guidance
- COVID-19 rapid guideline: managing COVID-19
- Number
- NG191
- Date issued
- March 2021
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 12/11/2021 |